Brian Wilson, Business Development Leader at Celanese, outlined the applications and development of Vital Dose EVA, a matrix copolymer used as a reservoir or membrane in various sustained delivery dose forms that maximise drug delivery. Compared with traditional dose forms, EVA-based systems address challenges such as targeting difficult sites and improving efficacy by reducing side effects and dosing frequency.
Furthermore, Vital Dose EVA offers continuous tunable release and broad molecular compatibility across a range of therapeutic areas. Wilson also commented that Vital Dose EVA has low regulatory risk compared to other polymers on the market.
In oncology and women’s health, there has traditionally been a focus on a systemic dosing regimen, but now there’s a growing interest in localised delivery approaches. In the fields of ophthalmology, oncology, and women’s health, EVA has been particularly useful because it can be dosed through a systemic dosing regime as well as a localised delivery approach. Celanese is also looking to break into the area of CNS and rare diseases.
Moving on to formulation flexibility, the material of the Vital Dose EVA allows for various design levers like polymer composition, multilayer configurations, and drug loading. Wilson showed an example of a circular peptide cyclosporine, an insoluble molecule that is loaded in a very simple design. He showed how the polymer composition could be altered to change the release profile. He also presented other examples of sodium naproxen and IgGs, and ASOs. This demonstrates the ability to achieve precise, tunable, and consistent drug release profiles for both soluble and insoluble molecules.
Celanese supports partners through a prototyping lab that enables development from concept to preclinical prototypes. They offer material supply with technical support, co-development services, and strategic partnerships to create platform technologies for multiple APIs. Overall, Vital Dose EVA is a patient-centric and adaptable solution for sustained drug delivery. It also supports many formulation and drug development needs.
